Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
SAN DIEGO, May 17, 2011 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Annual Meeting of Stockholders on Tuesday, May 24, 2011 at 9:00 a.m. PT/12:00 p.m. ET from the Company's corporate headquarters in San Diego, CA. Following the Annual Meeting, Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview.
To access the webcast, please log on to the "Investors" section of Amylin's corporate website at www.amylin.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (888) 396-2369 (U.S./Canada) or (617) 847-8710 (international), participant passcode number 89277424. A replay of the call will also be available by phone beginning approximately two hours after the close of the call and can be accessed at (888) 286-8010 (U.S./Canada) or (617) 801-6888 (international), passcode number 25483434.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.
You May Also Like